Moonwlkr was born out of the curiosity to push the boundaries of what is truly possible with hemp. By combining award-winning terpenes and natural flavors in unique, custom blends we explore new dimensions of taste, balance, and euphoria for all cannabinoids.
Cannabinoids are naturally occurring compounds found in the Cannabis sativa plant. Of over 450 different compounds present in the plant, only around 60 are termed cannabinoids.
The most known among these compounds is the delta-9-tetrahydrocannabinol (Δ9-THC), which is the main psychoactive ingredient in cannabis.
Cannabidiol (CBD) is another important component, which makes up about 40% of the plant resin extract and it’s a part of many products that you can find on the market today. Including our only Delta 8 Store where you can find all the products available on the market.
EFFECTS OF CANNABINOIDS
Cannabinoids exert their effects by interacting with specific cannabinoid receptors present on the surface of cells.
These receptors are found in different parts of the central nervous system and the two main types of cannabinoid receptors in the body are CB1 and CB2.
In 1992, a naturally occurring substance in the brain that binds to CB1 was discovered, called anandamide. This cannabinoid-like chemical and others that were later discovered are referred to as endocannabinoids.
The effects of cannabinoids depends on the brain area involved. Effects on the limbic system may alter the memory, cognition and psychomotor performance; effects on the mesolimbic pathway may affect the reward and pleasure responses and pain perception may also be altered.
Are Cannabis or Cannabinoids an Effective Treatment for Improving Sleep Outcomes?
The review by Whiting et al. (2015) was the most recent good-quality review. Two RCTs (54 participants) evaluated cannabinoids (nabilone, dronabinol) for the treatment of sleep problems. A trial deemed to have a high risk of bias conducted in 22 patients with obstructive sleep apnea showed a greater benefit of dronabinol (maximum dose of 10 mg daily) than with a placebo on sleep apnea/hypopnea index (mean difference from baseline −19.64, p = 0.02) at 3 weeks follow-up. A crossover trial deemed to have a low risk of bias in 32 patients with fibromyalgia found improvements for nabilone 0.5 mg daily compared with 10 mg amitriptyline in insomnia (mean difference from baseline, −3.25, 95% CI = −5.26 to −1.24) and greater sleep restfulness (mean difference from baseline, 0.48, 95% CI = 0.01–0.95) at 2 weeks follow-up. Although the antidepressant amitriptyline is an established treatment for fibromyalgia, it is not FDA approved for insomnia, and its use is limited by adverse effects.